Myndlift

Company Overview

Snapshot

Founded in June 2014 by Aziz Kaddan and Annas Abu-Mukh, Myndlift operates with 11–50 employees. The company has raised $3.2M across two disclosed funding rounds from six investors, including Corundum Neuroscience. In September 2022, Myndlift completed a study highlighting the efficacy of remote neurofeedback therapy for mental health.

Business overview

Myndlift is a Health Tech & Life Sciences company focused on digital therapeutics within the healthcare sector. The company develops an accessible, at-home neurofeedback platform that utilizes evidence-based techniques to enhance cognitive abilities without medication. Myndlift's core technology involves therapist-guided neurofeedback solutions, allowing patients to conduct brain training remotely while being monitored by certified therapists, thereby reducing costs and expanding access to mental health tools. The platform measures brain activity and retrains the brain, serving patients seeking alternative treatments for conditions like ADHD, anxiety, and depression.

Strategic signal

In September 2022, Myndlift, in partnership with Interaxon Inc. (Muse®), highlighted the preliminary results of a study demonstrating the efficacy of its remote neurofeedback therapy. The study, involving 593 participants, showed reduced symptom severity and adjusted resting EEG neural markers for individuals with ADHD symptoms, as well as positive outcomes for anxiety and depression. This signals strong validation for Myndlift's digital therapeutic approach, indicating its potential to offer an accessible and affordable alternative to traditional clinic-based EEG and medication for mental health conditions, thereby expanding its market reach and impact.

Company Intelligence Q&A

What significant study did Myndlift publish in August 2022?

In August 2022, Myndlift published a study demonstrating the efficacy of its remote neurofeedback system in improving mental health. The study, which evaluated Myndlift's model with 560 subjects, showed positive outcomes in reducing symptoms of ADHD, depression, and anxiety, with over 50% of participants demonstrating clinically significant improvement.

What was the focus of Myndlift's partnership with Interaxon Inc. (Muse®) in September 2022?

In September 2022, Interaxon Inc. (Muse®) highlighted Myndlift's preliminary study on the efficacy of remote neurofeedback therapy for mental health. The study, which utilized Muse's EEG technology, involved 593 participants and showed improved mental health outcomes, particularly for ADHD, anxiety, and depression.

What was the strategic focus of Myndlift in February 2021?

In February 2021, Myndlift was highlighted for making neurofeedback accessible through an app that allows users to retrain their brains via gaming with a neurofeedback headset and EEG electrodes. This initiative aimed to make neurofeedback therapy a frontier in mental health technology.

What was Myndlift's objective in February 2017 regarding ADHD treatment?

In February 2017, Myndlift aimed to provide an alternative non-drug treatment for attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) using neurofeedback. The company offered a mobile app and wearable technology to train the brain to focus and improve attention levels.